AR and prostate carcinoma: Specifically in prostate cancer (PC) cell plasticity allows cancer cells to reprogram and survive despite androgen receptor (AR) inhibition, being considered one of the mechanisms involved in androgen deprivation therapy (ADT) resistance (1).